Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 15/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781426 | 1.00 | TYK2 (0.47) | TYK2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3779985 | 0.93 | TYK2 (0.53) | TYK2PDE4D | |
| SCHEMBL3779987 | 0.93 | TYK2 (0.53) | TYK2PDE4D | |
| SCHEMBL3777327 | 0.93 | TYK2 (0.46) | TYK2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3777324 | 0.93 | TYK2 (0.46) | TYK2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14732096 | 0.92 | TYK2 (0.48) | TYK2PDE4DEPHX2POLB | |
| SCHEMBL13062625 | 0.92 | TYK2 (0.48) | TYK2PDE4DEPHX2POLB | |
| SCHEMBL3781922 | 0.92 | TYK2 (0.47) | TYK2NPC1RAB9APDE4DEPHX2 | |
| SCHEMBL3781925 | 0.92 | TYK2 (0.47) | TYK2NPC1RAB9APDE4DEPHX2 | |
| SCHEMBL3786962 | 0.91 | TYK2 (0.49) | TYK2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | claimed |
| EP-2240488-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP4K2, MAP3K15 | TYK2 289/4885NPC1 2805/4885RAB9A 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.